Moreover, the commonalities in CIP2A and RAS downstream effectors, as well as their synergistic effect on cancer cell growth, strongly suggest that studying the factors regulating PP2A activity will further the understanding of the responses to therapy targeting shared downstream pathways of RAS and PP2A. Here, PTPA is linked to cancer.